Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Journal of Thrombosis and Thrombolysis
Erschienen in: Journal of Thrombosis and Thrombolysis 1/2008

01.02.2008

Case studies in anticoagulation management

verfasst von: Wendy A. Leong

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Excerpt

As one of the most complex and widely prescribed drugs in North America, warfarin is a “hassle” drug due to its narrow therapeutic index, individualized dosing, INR monitoring, drug interactions, and high risk of bleed and patient noncompliance [1]. Fear of warfarin has led to under prescribing, subtherapeutic dosing and increased risk of thromboembolic events [1‐5]. …
Literatur
1.
Leong WA (2004) Anticoagulation opportunities for community pharmacists. Pharm Practice 20(11):CE1–8
2.
Ansell J, Hollowell J, Pengo V et al (2007) Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J Thromb Thrombolysis 23(2):83–91PubMedCrossRef
3.
Ansell JE, Oertel LB and Wittkowsky AK (eds) (2003) Managing Oral Anticoagulation: Clinical & Operational Guidelines, 2nd edn. Aspen Publishers, New York, NY
4.
Ansell JE, the Anticoagulation Guidelines Task Force (1997) Consensus guidelines for coordinated outpatient oral anticoagulation therapy management. Ann Pharmacother 31:604–615PubMed
5.
Ansell J, Hirsh J, Poller L et al (2004) The pharmacology and management of the vitamin K antagonists: the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:204S–233SPubMedCrossRef
6.
7.
Salem DN, Stein PD, Al-Ahmad A et al (2004) Antithrombotic therapy in valvular heart disease—native and prosthetic: the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:457S–482SPubMedCrossRef
8.
Hirsh J, Raschke R (2004) Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:188S–203SPubMedCrossRef
9.
Douketis JD, Woods K, Crowther MA (2005) Anticoagulation management of patients undergoing elective surgery who require temporary interruption of warfarin therapy. 2nd edn. McMaster University Dept. of Medicine and St. Joseph’s Healthcare, Hamilton, Canada
10.
Mannucci C, Douketis JD (2006) The management of patients who require temporary reversal of vitamin K antagonists for surgery: a practical guide for clinicians. Intern Emerg Med 1(2):94–95CrossRef
11.
Spyropoulos AC, Turpie AG, Dunn AS et al (2006) Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost 4(6):1246–1252PubMedCrossRef
12.
Dunn A (2006) Perioperative management of oral anticoagulation: when and how to bridge. J Thromb Thrombolysis 21(1):85–89PubMedCrossRef
13.
Meurin P, Tabet JY, Weber H et al (2006) Low-molecular-weight heparin as a bridging anticoagulant early after mechanical heart valve replacement. Circulation 113(4):564–569PubMedCrossRef
14.
O’Donnell MJ, Kearon C, Johnson J et al (2007) Brief communication: preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Ann Intern Med 146(3):184–187PubMed
15.
Deerhake JP, Merz JC, Cooper JV et al (2007) The duration of anticoagulation bridging therapy in clinical practice may significantly exceed that observed in clinical trials. J Thromb Thrombolysis 23(2):107–13PubMedCrossRef
16.
Douketis JD, Woods K, Foster GA et al (2005) Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery. Thromb Haemost 94(3):528–531PubMed
17.
Leong WA (1998) Outpatient deep vein thrombosis treatment models. Pharmacotherapy 18(6 Pt 3):170S–174SPubMed
18.
Hulse ML (1996) Warfarin resistance: diagnosis and therapeutic alternatives. Pharmacotherapy 16(6):1009–1017PubMed
19.
Rost S, Fregin A, Ivaskevicius V et al (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427(6974):537–541PubMedCrossRef
20.
Yasar AS, Balbay Y, Maden O et al (2007) Early mechanical mitral valve thrombosis in a patient with warfarin resistance. J Heart Valve Dis 16(2):200–202PubMed
21.
Holt RJ, Freytes CO (1983) Familial warfarin resistance. Drug Intell Clin Pharm 17(4):281–283PubMed
22.
Alving BM, Strickler MP, Knight RD et al (1985) Hereditary warfarin resistance. investigation of a rare phenomenon. Arch Intern Med 145(3):499–501PubMedCrossRef
23.
Dager WE, Dougherty JA, Nguyen PH et al (2007) Heparin-induced thrombocytopenia: treatment options and special considerations. Pharmacotherapy 27(4):564–587PubMedCrossRef
24.
Taylor LM, Smith KM (2005) The paradox of heparin-induced thrombocytopenia: future anticoagulation. Orthopedics 28(7):651–654PubMed
25.
Attassi K, Hershberger E, Alam R et al (2002) Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 34(5):695–698PubMedCrossRef
26.
Waldrep TW, Skiest DJ (2002) Linezolid-induced anemia and thrombocytopenia. Pharmacotherapy 22(1):109–112PubMedCrossRef
27.
Gerson SL, Kaplan SL, Bruss JB et al (2002) Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 46(8):2723–2726PubMedCrossRef
28.
Greinacher A, Warkentin TE (2006) Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update. Thromb Res 118(2):165–176PubMedCrossRef
29.
Gruel Y, Pouplard C, Nguyen P et al (2003) Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br J Hematol 121(5):786–792CrossRef
30.
Warkentin TE (2002) Heparin-induced thrombocytopenia: part 1. J Crit Illness 17(5):172–178
31.
Spinler SA, Dager WE (2003) Overview of heparin-induced thrombocytopenia. Am J Health Syst Pharm 60:S5–S11PubMed
32.
Spinler SA (2003) Managing heparin-induced thrombocytopenia: preventing life- and limb-threatening thrombosis. Am J Health Syst Pharm 60:S2–S4PubMed
33.
Girolami B, Girolami A (2006) Heparin-induced thrombocytopenia: a review. Semin Thromb Hemost 32(8):803–809PubMedCrossRef
34.
Keeling D, Davidson S, Watson H (2006) The management of heparin-induced thrombocytopenia. Br J Haematol 133(3):259–269PubMedCrossRef
35.
Warkentin TE, Greinacher A (2004) Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3 Suppl):311S–337SPubMedCrossRef
36.
Andreescu AC, Cushman M (2000) Case studies in heparin-induced thrombocytopenia. J Thromb Thrombolysis 10(Suppl):71–76PubMedCrossRef
37.
Nagao T, Ibayashi S, Fujii K et al (1995) Treatment of warfarin-induced hair loss with ubidecarenone. Lancet 346:1104–1105PubMedCrossRef
38.
Akihama T, Nakamoto Y, Shindo T et al (1983) Protective effects of Coenzyme Q10 on the adverse reactions of anthracycline antibiotics. Gan To Kagaku Ryoho (Cancer & Chemotherapy) 10(10):2125–2129, [Article in Japanese]
39.
Frishman WH, Brosnan BD, Grossman M et al (2002) Adverse dermatologic effects of cardiovascular drug therapy: part II. Cardiol in Rev 10(5):285–300CrossRef
40.
41.
Motel PJ (1990) Captopril and alopecia: a case report and review of known cutaneous reactions in captopril use. J Am Acad Dermatol 23(1):124–125PubMedCrossRef
42.
Thiedke C (2003) Alopecia in women. Am Fam Physician 67:1007–1014, 1017–1018
43.
Umlas J, Harken DE (1988) Warfarin-induced alopecia. Cutis 42(1):63–64PubMed
44.
Kaur M and Kern M (2002) Warfarin sodium induced alopecia. Pharmascript 25(7)
45.
Anon (1995) A close shave... warfarin induced alopecia. ADRB 173:655–658
46.
Wang YY, Po HL (2006) Enoxaparin-induced alopecia in patients with cerebral venous thrombosis. J Clin Pharm Ther 31(5):513–517PubMedCrossRef
47.
Sarris E, Tsele E, Bagiatoudi G et al (2003) Diffuse alopecia in a hemodialysis patient caused by a low-molecular-weight heparin, tinzaparin. Am J Kidney Dis 41(5):E15PubMed
48.
Qureshi GD, Reinders TP, Swint JJ et al (1981) Acquired warfarin resistance and weight-reducing diet. Arch Intern Med 141(4):507–519PubMedCrossRef
49.
Reese AM, Farnett LE, Lyons RM et al (2005) Low-dose vitamin K to augment anticoagulation control. Pharmacotherapy 25(12):1746–1751PubMedCrossRef
50.
Hartig C, Lang M, Weibert R (2007) Low-dose daily vitamin K supplement in patients anticoagulated with warfarin. Abstract presented at the anticoagulation forum 9th National Conference in Chicago, Illinois
51.
Ford SK, Misita CP, Shilliday BB et al (2007) Prospective study of supplemental vitamin K therapy in patients on oral anticoagulants with unstable international normalized ratios. J Thromb Thrombolysis 24(1):23–27, Epub 2007 Feb 24PubMedCrossRef
52.
Ford S, Moll S (2007) Supplemental vitamin K in patients on warfarin with unstable INRs. J Thromb Thrombolysis 24(1):23–27PubMedCrossRef
53.
Lim W, Crowther MA, Eikelboom JW (2006) Management of antiphospholipid antibody syndrome: a systematic review. JAMA 295(9):1050–1057PubMedCrossRef
54.
Ortel TL (2006) The antiphospholipid syndrome: what are we really measuring? How do we measure it? And how do we treat it? J Thromb Thrombolysis 21(1):79–83PubMedCrossRef
55.
Crowther MA, Wisloff F (2005) Evidence based treatment of the antiphospholipid syndrome II. Optimal anticoagulant therapy for thrombosis. Thromb Res 115(1–2):3–8PubMed
56.
Erkan D, Lockshin MD (2004) How much warfarin is enough in APS related thrombosis? Thromb Res 114(5–6):435–442PubMedCrossRef
57.
58.
Sucker C, Wenzel F, Zotz RB et al (2006) Monitoring oral anticoagulation may require determination of single coagulation factor activities in patients with antiphospholipid syndrome. J Rheumatol 33(9):1881–1882PubMed
59.
Moll S, Oertel TL (1997) Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 127(3):177–185PubMed
60.
Wittkowsky AK, Downing J, Blackburn J et al (2006) Warfarin-related outcomes in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic. Thromb Haemost 96(2):137–141PubMed
61.
Sconce E, Avery P, Wynne H et al (2007) Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 109(6):2419–2433PubMedCrossRef
Metadaten
Titel
Case studies in anticoagulation management
verfasst von
Wendy A. Leong
Publikationsdatum
01.02.2008
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 1/2008
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-007-0109-6

Weitere Artikel der Ausgabe 1/2008

Journal of Thrombosis and Thrombolysis 1/2008 Zur Ausgabe

Events

An analysis of anticoagulant adverse drug events in a large community teaching hospital

Events

Clinical challenges of management of a coumarin rodenticide (brodifacoum) toxicity vs. warfarin toxicity: case report

Events

Clinical and economic benefits of an anticoagulation management service (AMS) for cardiac surgery patients

Events

Low dose daily vitamin K supplementation in patients anticoagulated with warfarin

Events

Evaluation of warfarin prescription labels

OriginalPaper

Warfarin monitoring: point-of-care INR testing limitations and interpretation of the prothrombin time

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Ist Fasten vor Koronarinterventionen wirklich nötig?

04.06.2024 Interventionelle Verfahren in der Kardiologie Nachrichten

Wenn Eingriffe wie eine Koronarangiografie oder eine Koronarangioplastie anstehen, wird häufig empfohlen, in den Stunden zuvor nüchtern zu bleiben. Ein französisches Forscherteam hat diese Maßnahme hinterfragt.

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

04.06.2024 Typ-2-Diabetes Nachrichten

Wenn ältere Menschen mit Typ-2-Diabetes Schwierigkeiten beim Beschaffen und Zubereiten von Mahlzeiten haben, geht dies mit einem deutlich gesteigerten Risiko für schwere Hypoglykämien einher.

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

03.06.2024 Semaglutid Nachrichten

Der GLP-1-Agonist Semaglutid hat in der FLOW-Studie bewiesen, dass sich damit die Progression chronischer Nierenerkrankungen bei Patienten mit Typ-2-Diabetes bremsen lässt. Auch in kardiovaskulärer Hinsicht war die Therapie erfolgreich.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise